Bridging the Gap: Index Volume [International Conference on AIDS (12th: 1998: Geneva, Switzerland)]

12th World AIDS Conference

profile * prophylaxis 157

SKeyword

Abstract

SKeyword

Abstract

ty of life, psychological and economic aspects of the advan
al/Efficacy and safety of antiretroviral treatment of ritonavi
c/Construction of a risk among male homosexual attendee
women/Psycho-social in Indian HIV seropositive women/
1996/Epidemiological of women over age 15 at risk or infe
ct drugs (MSM-IDU): A of the group at highest risk for HIV tr
hanghai/Demographic and HIV risk behavior among femal
ysis of the psychosocial of HIV-infected adults in Montreal,
Study of immunological in HIV exposed seronegative subje
eroon)/Immunological of HIV infected patients at the time t
Paulo/Epidemiological of the population spontaneously su
V properties, resistance and safety of dOTC (2'-deoxy-3'-ox
abacavir/Susceptibility (AntivirogramTM) of 945 clinical HIVrst study on resistance in a group of drug naive patients in
nfections/Cytological in bronchoalveolar lavage (BAL) flu
abaya, Indonesia/Risk of female sex workers who particip
AIDS: Epidemiological, spacial distribution and informal tre
ry of Health/Economic of patients beneficiary of therapeuti
S in Pretoria - A clinical /Ten years of AIDS in Pretoria - A cl
ountry/Impact of the of the national AIDS program direct
he HIV RT resistance of patients receiving AZT and either
s apart/Changes in the of HIV infected patients five years a
al therapy prescription in a multicenter cohort of HIV+ preg
rment in hematopoietic progenitor cells (CD34+) of HIV-1 infected
he female genital tract: Progesterone increases CCR5, CXCR4,
lationship with different prognosis markers/Endothelial cell dysfu
vation of viral load as a marker of failure in triple antiret
e Frankfurt HIV-Cohort/ Prognostic value of virus load levels in pat
ents with HIV infection/ factors of hospitalized patients
etroviral therapy on the prognostic value of CD4 cell counts: The
atients. Prevalence and value/Hepatitis C in the EuroS
virus in CSFAND urine value of CSF JC viral load in p
C)/Characteristics and factors for AIDS dementia com
oad and CD4 T cells as indicators/Plasma immune ac
m RANTES as an early marker of HIV-1 disease progr
ical and immunological criteria in HIV infected children
unological markers with value for HIV progression in Et
isease in rural Uganda/ Progression of HIV-1 disease in rural Uga
1 infection and disease progression /Positive selection of Vpr in h
rapid or a slow disease /Genetic evolution of HIV-1 s
V leads to rapid disease and renders trypanocidal the
ith HIV and HBV on the to AIDS and death: Evidence
counts and HIV disease in subjects co-infected with H
d and other markers for to clinical AIDS after CD4+ c
nsmission and disease /Role of CCR5 chemokine re
on does not affect HIV-1 in perinatally infected childre
y followed by the use of predictors/Two antiretroviral
r immunologic disease with transient use of zidovudi
3TC + indinavir) in the of chronic HIV-1 infected pati
n March 1996/Clinical and adverse events in a coho
actors associated with to a new AIDS defining event
3TC and AZT/Disease and survival on triple therapy
y in regional HIV spread: 1997 incidence over 1997 pr
hern Thailand/Disease and mortality among HIV-infe
1986 in Cuba/Disease in a cohort of HIV+ individual
mmunological disease in 410 HIV infected seroconv
on mutation on disease in HIV infected injecting drug
the risk of HIV disease /Production of /-chemokines
s (HCV) genotypes and of HIV infection in hemophilia
edicting HIV-1 disease after knowing plasma HIV-1
otypes and HIV disease: A preliminary meta-analysis
991-1997/HIV disease following newly acquired HIV
leles on HIV-1 disease in 426 patients with a known
associated with slower to AIDS?/Amsterdam cohort
ated with HIV-1 disease among injection drug users/
I changes on the rate of to AIDS in the HIV-Italian ser
r Study/Risk factors for to primary and subsequent A
ell counts and disease in a Danish cohort of HIV infe
A/Direct comparison of to AIDS and death among HI
onverters/Survival and to AIDS up to 1996 in 13,000
hic variation in disease in 664 HIV-1 seroconverted i
cial factors affecting the of the HIV-disease in homos
resources, survival and of the HIV infection/Economi
of mortality and disease in HIV-1 infection/Psycholog
(LTNPs)/Probability of and predictivity of immunolog

al indicators of disease in a perinatal HIV cohort: The
virus load, and disease in perinatally infected infants
HIV-1 infection/Disease in perinatal HIV-1 infection/D
AIDS case definition on rates to AIDS in drug users/
etween HIV-1 load and to AIDS/Gender differences i

22392
22409
23135
23482
23483
23550
23576
24233
31146
31179
33278
41196
41226
41227
60281
60355
60563
60617
60732
60750
60854
60948
61001
21118
335*/21109
12139
60448
12129
12130
12106
22261
22266
32220
42181
43101
60117
60880
12131
11147
11173
11229
12108
12113
12133
12162
12170
12182
12233
12238
440*/12266
12282
12317
13104
13135
13167
13183
13304
13305
13306
13308
13311
13313
13320
13321
13322
13323
13325
13327
13332
13337
192*/13338
13340
13343
595*/13345
13351

13368
13369
13371
13383
13384

repertoire indicate fast
ilar immune activation,
o viral load and predicts
ates with HIV-1 disease
D8+ cell subsets during
pic switch and disease
rrelates of HIV disease
nts/Low CMV disease
nd ARV therapies in the
mbinations on disease
holistic approach on the
nd subsequent disease
orrelation with disease
activation and disease
ection predicts disease
erent effects of disease
les/Cervical dysplasia
f splenectomy on AIDS
ve outcomes as well as
s that related to disease
netic factor on disease
F-a/Predicting clinical
et of CD8 cells predicts
ors associated with the
omeopathy for delaying
marker of HIV-1 disease
long-term HIV disease
apy/Modelling disease
ort study slows disease
ated with long-term non
infection/Predictors of
rogression/Disease
ion and function during
deficiency/Gender and
otype predicts disease
rognostic value for HIV
reatment with cidofovir/ Progressive
ing protease inhibitors/
uences/Long-term non- progressive
ral load in patients with
ing the development of
RT)/The occurrence of
ntrols with and without
nt with HIV-associated
associated with rapidly
V-infected adults using
mbined with HAART for

to disease in SIV infection/P
and response to treatment/I
of HIV disease/Complement
/Adaptation to promiscuous u
of HIV disease/Alteration of i
/Differential effects of IL-4 on
/sCD30 and RANTES are pot
after initiation of protease-inh
of cervical disease/Trying to
and survival in HIV infected p
of HIV disease (8 years folio
/Correlation between humor
/Bulk measurements of HIVin HIV+ children/The expres
/Alterations of CD45 isoform
and combination antiretrovir
rates over 1 year and HIV tes
and survival in HIV-associate
to AIDS and death in HIV infe
of HIV-1 infection/HIV-1 reve
rate/Formal analysis of the ti
and death in a cohort of HIV-i
to AIDS in long-term survivin
of HIV infection in pediatric p
of HIV disease/Use of home
/Serum RANTES as an early:A population model for Scotl
in HIV-infected patients witho
and improves survival/Early
of HIV infection/HLA antigen
of the human immunodeficie
markers in HIV infection; a co
of HIV-1 infection and T-cell
of HIV-associated immunode
and viral load levels in a coho
in Ethiopians/Immunological
multifocal leukoencephalopa
multifocal leucoencephalopa
transition to progressive HIVmultifocal leukoencephalopa
multifocal leukoencephalopa
multifocal leukoencephalopa
multifocal leukoencephalopa
multifocal leukoencephalopa
outer retinal necrosis (PORN
resistance training/Feasibilit
multifocal leucoencephalopa

21104
21105
21132
8*/21134
217*/21171
218*/21174
21183
22257
22321
22360
22484
31107
31156
213*/31166
31176
32112
32131
32145
32195
42115
42146
42188
42191
42366
42377
43101
43471
43474
60208
60249
60360
60393
60649
60844
60870
60880
562*/32193
32194
21127
22266
22322
32199
32210
32221
32246
42357
60963
13356
60250
34190
23208
21133
22413
11216
12371

children long-term non progressor verically infected with HIV-1: I
eletion in long-term non progressors, and its viro-immunological c
munity in Geneva/The " Projet Parc": AIDS prevention among the L
ting drug users (IDUs)/ Projeto Brasil-Rio De Janeiro, preventing
-infected patients/High prolactin levels in the cerebrospinal fluid o
atients/Experience with proleukin (rlL2) in HIV-infected patients/E
ated simian lymphoma/ Proliferation and apoptosis-related gene
HIV replication and cell proliferation leads to minimal levels of pro

ystem/Control of HIV-1 and pathogenesis with host f 276*/21102
tment/No evidence for in blood CD4+ T cells during 21121
in-15 on apoptosis and of T lymphocytes of HIV-infe 280*/21162
es/Stimulation of T-cell byTNF-a produced by HIV-1 21168
SI viruses enhance cell and beta-chemokine product 21175
sarcoma (KS)/HHV-8,, apoptosis and ploidy in epid 620*/22282
d antigen specific T-cell in HIV-2 exposed non-infecte 605*/31133
ut impairment of cellular /Efficacy of aminooxypentan 59*/41231
ge granular lymphocyte during HIV infection/Large gr 60871
de: TAB 9/Lymphocyte proliferative response following immuniza 21215
hildren: Correlation with responses/T lymphocytes ex 31173
QV/stavudine (d4T) (the Prometheus study): Preliminary results/T 291*/12274
ent clinics - The Zurich study/Nelfinavir, didanosine 42281
ution clinics: The ZOrich study/Prior experience with 42290
tion clinics: The ZOrich study/High refusal rates for s 43135
ts to establishment and propagation of self-help groups of the HIV 34290
nsmission in the time of prophylactic zidovudine/HIV-1 vertical tra 23303
n of vaccine efficacy for HIV vaccines from field trials 43552
cilitate access to AIDS prophylactics in developing countries/A g 42320
City: The importance of prophylaxis and antiviral treatment/HIV p 12111
uroSIDA Study/Can for PCP and cerebral toxopla 12268
der noncompliance with for Pneumocystis carinii pneu 13234
ntrolled trials/Isoniazid for tuberculosis in HIV infectio 451*/22124
entation of universal TB /Characteristics of the new ca 22155
compliance to primary therapy to tuberculosis (TB) i 22156